***Background.*** Antibiotic drugs are the standard treatment for community-acquired bacterial pneumonia (CABP) but are associated with the development of bacterial resistance and side-effects. This study estimates the rate of adverse events, hospitalizations and treatment failure following outpatient treatment with antibiotics, and compares them by type of antibiotic administered.

***Methods.*** CABP episodes were identified in the Truven database between January 1, 2007 and December 31, 2012 in patients 18 years of age or older with a pneumonia diagnosis and treated with monotherapy beta-lactam (BL), fluoroquinolone (FQ), or macrolide (M) preceded by both ≥30 days free of institutional care and ≥90 days free of antibiotic use. The effects of monotherapies BL vs M and FQ vs M on risk of adverse events, pneumonia-related hospital visits and treatment failure within 30 days of CABP episode were estimated after adjusting for pre-treatment demographics, health care resource use and costs using multivariate regression models. Treatment failure was defined as switch in drug class ≥ 6 days after initial CABP treatment.

***Results.*** Out of a total of 441,820 CABP patients, 84% were initiated with the following monotherapies: BL (N = 36,702), FQ (165,768) and M (N = 169,335). Comparing the three cohorts revealed that patients receiving FQ therapy were the oldest while BL treated patients were the sickest. FQ vs M initiation was associated with an increased risk of an adverse event (OR = 1.23, 95% CI: 1.20-1.25), increased 30-day odds of pneumonia-related hospital visits (OR = 1.83, 95% CI: 1.69-1.98) and a reduced 30-days odds of treatment failure (OR = 0.90, 95% CI: 0.87-0.94). BL vs M initiation was associated with an increased risk of an adverse event (OR = 1.26, 95% CI: 1.23-1.31), increased 30-day odds of pneumonia-related hospital visits (OR = 1.72, 95% CI: 1.53-1.93) and an increased 30-days odds of treatment failure (OR = 1.27, 95% CI: 1.20-1.35).

***Conclusion.*** Compared to initiating outpatient CABP treatment with M monotherapy, initiation with FQ or BL monotherapy was associated with a significantly increased risk of an adverse event and pneumonia-related hospital visit. The risk of treatment failure was reduced with FQ but increased with BL. Thus, treatments are needed that are both effective and have few side effects.
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